Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions

被引:221
作者
Raad, II
Hachem, RY
Herbrecht, R
Graybill, JR
Hare, R
Corcoran, G
Kontoyiannis, DP
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77230 USA
[2] Univ Texas, Hlth Sci Ctr, San Antonio, TX USA
[3] Plough Res Inst, Kenilworth, NJ USA
[4] Steifel Labs, Coral Gables, FL USA
[5] Hop Univ Strasbourg, Strasbourg, France
关键词
D O I
10.1086/503425
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Conventional amphotericin B-based antifungal therapy for invasive fusariosis in patients with a hematologic malignancy results in a >= 70% failure rate. Posaconazole is a broad-spectrum antifungal agent with in vitro and in vivo activity against Fusarium species. Methods. In this retrospective analysis of patients from 3 open-label clinical trials, we evaluated posaconazole for the treatment of invasive fusariosis. Twenty-one patients with proven or probable invasive fusariosis who had disease refractory to or who were intolerant of standard antifungal therapy received oral posaconazole suspension (800 mg per day in divided doses) as salvage therapy. Results. Successful outcome occurred in 10 (48%) of all 21 patients. Among patients with leukemia who received posaconazole therapy for 13 days, the overall success rate was 50%; for patients who recovered from myelosuppression, the success rate was 67%, compared with 20% for those with persistent neutropenia. Conclusion. These results suggest that posaconazole is useful for the treatment of invasive fusariosis.
引用
收藏
页码:1398 / 1403
页数:6
相关论文
共 18 条
[1]   THE EMERGING ROLE OF FUSARIUM INFECTIONS IN PATIENTS WITH CANCER [J].
ANAISSIE, E ;
KANTARJIAN, H ;
RO, J ;
HOPFER, R ;
ROLSTON, K ;
FAINSTEIN, V ;
BODEY, G .
MEDICINE, 1988, 67 (02) :77-83
[2]   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[3]   Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management [J].
Boutati, EI ;
Anaissie, EJ .
BLOOD, 1997, 90 (03) :999-1008
[4]   Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2950-2956
[5]   The epidemiology of fusariosis in patients with haematological diseases [J].
Girmenia, C ;
Pagano, L ;
Corvatta, L ;
Mele, L ;
Del Favero, A ;
Martino, P .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) :272-276
[6]   Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections [J].
Herbrecht, R .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (06) :612-624
[7]   Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].
Herbrecht, R ;
Denning, DW ;
Patterson, TF ;
Bennett, JE ;
Greene, RE ;
Oestmann, JW ;
Kern, WV ;
Marr, KA ;
Ribaud, P ;
Lortholary, O ;
Sylvester, R ;
Rubin, RH ;
Wingard, JR ;
Stark, P ;
Durand, C ;
Caillot, D ;
Thiel, E ;
Chandrasekar, PH ;
Hodges, MR ;
Schlamm, HT ;
Troke, PF ;
de Pauw, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415
[8]   Outcome determinants of fusariosis in a tertiary care cancer center: The impact of neutrophil recovery [J].
Kontoyiannis, DP ;
Bodey, GP ;
Hanna, H ;
Hachem, R ;
Boktour, M ;
Girgaway, E ;
Mardani, M ;
Raad, II .
LEUKEMIA & LYMPHOMA, 2004, 45 (01) :139-141
[9]   Treatment of murine fusariosis with SCH 56592 [J].
Lozano-Chiu, M ;
Arikan, S ;
Paetznick, VL ;
Anaissie, EJ ;
Loebenberg, D ;
Rex, JH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (03) :589-591
[10]  
Musa MO, 2000, BRIT J HAEMATOL, V108, P544, DOI 10.1046/j.1365-2141.2000.01856.x